T2 Biosystems (T2 Biosystems) Insider Ownership : 26.70 % (As of Apr. 27, 2024)

View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, T2 Biosystems's insider ownership is 26.70%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, T2 Biosystems's Institutional Ownership is 0.95%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, T2 Biosystems's Float Percentage Of Total Shares Outstanding is 90.63%.

T2 Biosystems Insider Ownership Historical Data

The historical data trend for T2 Biosystems's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Insider Ownership Chart

T2 Biosystems Historical Data

The historical data trend for T2 Biosystems can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Insider Ownership	9.66	0.83	0.59	0.59	34.40	33.26	33.26	33.26	32.51	26.70

T2 Biosystems Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

T2 Biosystems (T2 Biosystems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.t2biosystems.com

T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.

Executives

Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs	officer: General Counsel	12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague	officer: Chief Financial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii	director, officer: See Remarks	61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin	officer: Chief Commercial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay	officer: SVP, Operations	101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja	officer: Chief Medical Officer	101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams	director	101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare	officer: Chief Commercial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard	director	101 HARTWELL AVENUE, LEXINGTON MA 02421